CA2485337C - Analgesic composition and method - Google Patents

Analgesic composition and method Download PDF

Info

Publication number
CA2485337C
CA2485337C CA002485337A CA2485337A CA2485337C CA 2485337 C CA2485337 C CA 2485337C CA 002485337 A CA002485337 A CA 002485337A CA 2485337 A CA2485337 A CA 2485337A CA 2485337 C CA2485337 C CA 2485337C
Authority
CA
Canada
Prior art keywords
sodium channel
opioid
morphine
channel blocking
blocking compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002485337A
Other languages
English (en)
French (fr)
Other versions
CA2485337A1 (en
Inventor
Baoshan Ku
Frank Hay Kong Shum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Medical Ltd
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Publication of CA2485337A1 publication Critical patent/CA2485337A1/en
Application granted granted Critical
Publication of CA2485337C publication Critical patent/CA2485337C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002485337A 2001-05-18 2002-05-20 Analgesic composition and method Expired - Fee Related CA2485337C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN01118098.6 2001-05-18
CNB011180986A CN1269482C (zh) 2001-05-18 2001-05-18 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
PCT/CN2002/000339 WO2002094272A1 (en) 2001-05-18 2002-05-20 Analgesic composition and method

Publications (2)

Publication Number Publication Date
CA2485337A1 CA2485337A1 (en) 2002-11-28
CA2485337C true CA2485337C (en) 2007-08-28

Family

ID=4662967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002485337A Expired - Fee Related CA2485337C (en) 2001-05-18 2002-05-20 Analgesic composition and method

Country Status (9)

Country Link
US (2) US6780866B2 (https=)
EP (1) EP1387685B1 (https=)
JP (1) JP2004529959A (https=)
CN (1) CN1269482C (https=)
AT (1) ATE464903T1 (https=)
CA (1) CA2485337C (https=)
DE (1) DE60236077D1 (https=)
ES (1) ES2344631T3 (https=)
WO (1) WO2002094272A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
JP2007536269A (ja) * 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4906779A (en) * 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
WO1995023132A1 (en) * 1994-02-23 1995-08-31 Cambridge Neuroscience, Inc. Blockers of ion channels and methods of use thereof
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
GB9513180D0 (en) * 1995-06-28 1995-08-30 Univ London Ion channel
DE19602970A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue 7,8- Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
CN1081034C (zh) * 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
DE19936719A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
US20040214842A1 (en) 2004-10-28
CN1386505A (zh) 2002-12-25
DE60236077D1 (de) 2010-06-02
JP2004529959A (ja) 2004-09-30
EP1387685A1 (en) 2004-02-11
EP1387685B1 (en) 2010-04-21
CN1269482C (zh) 2006-08-16
US6780866B2 (en) 2004-08-24
US20020198226A1 (en) 2002-12-26
WO2002094272A1 (en) 2002-11-28
ES2344631T3 (es) 2010-09-02
CA2485337A1 (en) 2002-11-28
EP1387685A4 (en) 2007-05-23
ATE464903T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
Shimoyama et al. d-Methadone is antinociceptive in the rat formalin test
CA2485337C (en) Analgesic composition and method
CA2336902C (en) Topical compositions comprising an opioid analgesic and an nmda antagonist
Fürst et al. Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat
US20100227876A1 (en) Methods of Reducing Side Effects of Analgesics
JP2002507962A (ja) トラマドールとｎｍｄａの組合せによる痛み軽減法
JP2007507538A (ja) 疼痛軽減方法
ES2283049T3 (es) (d)-metadona, un analgesico no opiaceo.
KR20110021823A (ko) 진통 내성 억제제
Dehpour et al. Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
EP0906757B1 (en) Analgesic composition comprising moxonidine and an opioid analgesic agent
HUP0302767A2 (hu) Hisztamin receptor antagonista hatóanyagok
Dow-Edwards et al. Cerebral metabolic interactions between thyroid state and imipramine in the rat.
JP2015500278A (ja) Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物
RU2323725C1 (ru) Композиция для купирования проявлений опиатного абстинентного синдрома
Miranda et al. Opioid antagonism in fentanyl antinociception experimental
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1702627A1 (en) Analgesic combination of sodium channel blockers with opioid antagonists
WO2021087268A1 (en) Novel selective kappa opioid receptor antagonists and methods related thereto for treatment of addiction and neuropathic pain
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
EP1000623A1 (en) Use of epinastine as antitussivum
Healthcare The antiemetic 5-HT3 receptor antagonist palonosetron inhibits Substance P-mediated responses in vitro and in vivo
US20090281194A1 (en) Combinations for treating HIV-associated pain

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130521